Health Care/Hospital

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin imp...

2026-08-20 08:02 3201

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer

oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 NATICK, Mass. and TOKYO, Aug. 20, 2026 /PRNewswire/ -- Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medie...

2026-08-20 06:00 2330

Dubai Police Initiatives Drive $176.4 Million in Social Value and Gains in Safety, Wellbeing and the Economy, Study Reveals

DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ -- A study has estimated the Social Return on Investment (SROI) of 80Dubai Police  community initiatives at AED 647.9 million ($176.4 million), reflecting the wider social, economic and security value created for 3.8 million b...

2026-08-19 22:12 2491

DrFirst Receives Frost & Sullivan's 2026 North America Enabling Technology Leadership Recognition for Advancing AI-Enhanced Medication Orchestration

DrFirst is honored for redefining medication management with its scalable platform that embeds intelligence directly in prescribing, making it more efficient for providers, pharmacies, and patients. SAN ANTONIO, Aug. 19, 2026 /PRNewswire/ -- As healthcare organizations continue to navigate fragm...

2026-08-19 21:00 1857

ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights

The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ -- ZEISS Medical Tech...

2026-08-19 21:00 2067

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the g...

2026-08-19 19:46 2045

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Scie...

2026-08-19 19:45 2766

So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026

BEIJING, Aug. 19, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it will report its financial results for the seco...

2026-08-19 18:00 1256

Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care

Patients from Australia, India, Indonesia, South Korea and Singapore gathered at Edwards Lifesciences' annual APAC Patient Experience event to share their stories and help advance more patient-centered care. SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- As structural heart disease continues to impact...

2026-08-19 17:11 1363

NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product

WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...

2026-08-19 17:00 1517

MALAYSIA AND BANGLADESH TRANSLATE LEADERS' COMMITMENT INTO HEALTHCARE COOPERATION

Health Ministry Seeks Affordable Malaysian Healthcare for Bangladeshi Patients DHAKA, Bangladesh, Aug. 19, 2026 /PRNewswire/ -- A delegation from Malaysia Healthcare Travel Council (MHTC), led by H.E. Mohd Shuhada Othman, High Commissioner of Malaysia to Bangladesh, met with H.E. Sardar Md. Sakha...

2026-08-19 16:43 1855

Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...

2026-08-19 14:48 1113

Everest Medicines Announces Interim Results for First Half of 2026

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...

2026-08-19 11:39 2785

Hi & Fi Asia-China 2026 Concludes in Shanghai with Record Numbers, Handing the Baton to Hi & Fi Shenzhen This Autumn

Connecting Global Health & Food Ingredient Suppliers with Greater Bay Area Opportunities from 13–15 October 2026 at Shenzhen World SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- The 27th Hi & Fi Asia-China 2026 concluded successfully in Shanghai in June, setting historic records. Centered on the theme ...

2026-08-19 10:00 1657

GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma

* Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 * Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed [...

2026-08-19 10:00 2192

Ping An Good Doctor Announces 2026 Interim Results

Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim ...

2026-08-19 09:09 2363

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-19 09:00 1796

CARsgen Therapeutics Announces 2026 Interim Results

SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...

2026-08-19 08:15 3422

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...

2026-08-19 03:44 1850

/C O R R E C T I O N -- Rayence/

In the news release, Rayence Breaks the Boundaries of Point-of-Care Imaging with the Launch of Integrated Portable X-ray Diagnostic Solutions 'Anywhere-M' and 'Anywhere-V', issued 18-Aug-2026 by Rayence over PR Newswire, we are advised by the company that the first paragraph has been updated and ...

2026-08-19 01:22 2586
1 ... 19202122232425 ... 846

Week's Top Stories